Home  /  Resource Library  /  MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN IS SUPERIOR TO R-GemOx IN TRANSPLANT-INELIGIBLE PATIENTS WITH R/R LBCL: PRIMARY RESULTS OF THE PHASE III SUNMO TRIAL

MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN IS SUPERIOR TO R-GemOx IN TRANSPLANT-INELIGIBLE PATIENTS WITH R/R LBCL: PRIMARY RESULTS OF THE PHASE III SUNMO TRIAL

ICML 2025